Sunday, July 12, 2026
Preview mode — showing bulk-ingested data not yet promoted to production. Hide preview

TGA / PMDA / NMPA · Asia-Pacific

fluocinolone — TGA / PMDA / NMPA regulatory status

fluocinolone regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.

Status snapshot

Status
NMPA clinical trials
Structured fields
3

Regional decision snapshot — NMPA: clinical trials.

Linked evidence on this spoke: 6 published clinical programs and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.

Regulatory timeline

Regulator Region Status Date Source
NMPA China clinical trials Evidence

Linked clinical programs

Related hubs

FAQ

What is the TGA / PMDA / NMPA approval status of fluocinolone?

fluocinolone currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.

Where does NovaPharmaNews get fluocinolone regulatory data?

Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.

How many clinical programs are linked to fluocinolone?

This spoke lists 6 published programs associated with fluocinolone in our pipeline index.